PT-141 (Bremelanotide) research guide for Recloses. Melanocortin-4 receptor agonist studied for sexual function — covers purity standards, COA testing, and sourcing.
For anyone in Recloses trying to locate PT-141 (Bremelanotide), the first thing to know is that this compound is distributed via specialist online vendors. What this means for Recloses researchers is that geography is secondary to your ability to verify analytical documentation — and those verification methods are accessible to anyone. The key verification criteria for PT-141 (Bremelanotide) are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. This guide guides Recloses researchers through that evaluation process and explains how to verify PT-141 (Bremelanotide) vendor quality step by step.
PT-141 (Bremelanotide): What the Research Shows
PT-141 (Bremelanotide) falls within a class of peptides studied for dermatological and aesthetic biology applications. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is one of the most extensively studied cosmetic peptides, with documented activity in promoting collagen I and collagen III synthesis in fibroblast cultures, activating antioxidant enzymes, and promoting wound healing. Its copper-chelating properties make it mechanistically distinct from non-metallopeptides in the aesthetic category. Melanotan-2 (MT-2) is a cyclic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that acts on melanocortin receptors — primarily MC1R in melanocytes for pigmentation effects and MC4R in the hypothalamus for other documented effects. For researchers in Recloses studying skin biology, pigmentation, or melanocortin receptor pharmacology, these compounds offer mechanistically specific research tools.
How to Source PT-141 (Bremelanotide) — Vendor Guide
Evaluating PT-141 (Bremelanotide) vendors requires starting from the COA: access the batch-specific certificate prior to buying, not after. A COA for PT-141 (Bremelanotide) should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. Negative indicators in PT-141 (Bremelanotide) vendor evaluation: prices far under typical market pricing, unclear production details, no community presence, and COAs that omit endotoxin testing. Store lyophilised PT-141 (Bremelanotide) at minus 20 degrees Celsius until ready to use; reconstitute only the volume needed for upcoming use and store the rest at −20°C.
Order PT-141 (Bremelanotide) — ships to Recloses
COA-verified · International tracking · Research grade
PT-141 (Bremelanotide) is available for research use only and is not approved for human therapeutic use by the FDA or equivalent regulatory bodies — all information here is for educational purposes only. Temperature excursions — even short periods above −20°C — can compromise product integrity without any obvious sign; always maintain cold chain and work with cold-shipped material. The main safety concern arising from sourcing in PT-141 (Bremelanotide) research is endotoxin contamination from poor sourcing — a verified endotoxin panel in the batch COA is the key safeguard. Protocol documentation — recording exactly what was used, when, and how — is a research best practice for PT-141 (Bremelanotide) that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist developed from Melanotan-2. Unlike MT-2, PT-141 acts primarily on MC3R and MC4R receptors in the CNS rather than MC1R in melanocytes. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. As a research compound it is studied for melanocortin receptor pharmacology.
What is the regulatory status of PT-141?
PT-141 (as Bremelanotide/Vyleesi) is an FDA-approved pharmaceutical in the US for HSDD in premenopausal women. This pharmaceutical status means it is more tightly regulated than pure research compounds in most jurisdictions. Import and possession regulations vary by country — verify current status in your jurisdiction before ordering.
How does PT-141 differ from Melanotan-2?
Both are melanocortin receptor agonists, but PT-141 is more selective for MC3R/MC4R (CNS-expressed receptors) while MT-2 has broader activity including MC1R (melanocytes) for pigmentation. PT-141 was specifically developed from MT-2 to have the CNS effects with reduced pigmentation side effects.
